Markets:

Overview

News

Currencies

International

Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.778 +0.028 (+0.75%)

Streaming Delayed Price Updated: 1:27 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

22 23 Next >

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead ↗

March 18, 2024

This company's growth story is about to get moving with gusto.

Via The Motley Fool

Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗

March 14, 2024

Via Benzinga

Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics ↗

March 13, 2024

Via Benzinga

Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗

March 07, 2024

Via Benzinga

1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? ↗

March 07, 2024

Its revenue is set to grow, and one of its trials is no longer paused.

Via The Motley Fool

(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗

March 01, 2024

Via Benzinga

Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity ↗

February 29, 2024

Via Benzinga

Iovance Biotherapeutics: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst ↗

March 06, 2024

With its first approval in hand, attention is now on the top line.

Via The Motley Fool

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

March 04, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Could Iovance Biotherapeutics Stock Help You Become a Millionaire? ↗

March 02, 2024

Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?

Via The Motley Fool

Iovance Biotherapeutics to Present at Upcoming Conferences

March 01, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics's Earnings: A Preview ↗

February 27, 2024

Via Benzinga

Is Iovance a Buy After Its First Regulatory Win? ↗

February 25, 2024

Iovance Biotherapeutics has found a new way to treat cancer.

Via The Motley Fool

Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics ↗

February 23, 2024

Via Benzinga

Why Iovance Biotherapeutics Stock Got Trounced on Thursday ↗

February 29, 2024

A robust rally ended abruptly with the publication of the company's latest fundamentals.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy? ↗

February 29, 2024

More gains might be on the way for this high-flying biotech stock.

Via The Motley Fool

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

February 28, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

3 Stocks Flashing Recent Insider Buying Signals ↗

February 27, 2024

One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company.

Via InvestorPlace

Iovance Biotherapeutics Unusual Options Activity For February 22 ↗

February 22, 2024

Via Benzinga

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 ↗

February 26, 2024

Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.

Via InvestorPlace

1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street ↗

February 26, 2024

A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof.

Via The Motley Fool

This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst ↗

February 23, 2024

It has good news in hand and plenty of room to grow.

Via The Motley Fool

2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value ↗

February 23, 2024

These two businesses have viable paths to making investors richer -- possibly soon.

Via The Motley Fool

Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024

February 22, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 21, 2024

Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

February 21, 2024

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.